Matching articles for "Zynteglo"

Betibeglogene Autotemcel (Zynteglo) for Beta Thalassemia (online only)

   
The Medical Letter on Drugs and Therapeutics • September 30, 2024;  (Issue 1712)
Betibeglogene autotemcel (Zynteglo — Bluebird Bio), an autologous lentiviral vector cell-based gene therapy, has been approved by the FDA for one-time treatment of transfusion-dependent beta...
Betibeglogene autotemcel (Zynteglo — Bluebird Bio), an autologous lentiviral vector cell-based gene therapy, has been approved by the FDA for one-time treatment of transfusion-dependent beta thalassemia in children and adults. Exagamglogene autotemcel (Casgevy), a cell-based gene therapy that uses CRISPR/Cas9 gene-editing technology, was approved earlier this year for the same indication in patients ≥12 years old.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):e167-8 | Show Full IntroductionHide Full Introduction

In Brief: Casgevy for Beta Thalassemia

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024;  (Issue 1702)
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old...
Exagamglogene autotemcel (Casgevy – Vertex), a cell-based gene therapy recently approved for treatment of sickle cell disease1, has now been approved by the FDA for treatment of patients ≥12 years old with transfusion-dependent beta thalassemia. Casgevy is the first gene therapy that uses CRISPR/Cas9 gene-editing technology to be approved in the US for any disorder. Betibeglogene autotemcel (Zynteglo), an autologous lentiviral vector cell-based gene therapy, was approved in the US in 2022 for treatment of transfusion-dependent beta thalassemia.
Med Lett Drugs Ther. 2024 May 13;66(1702):79 | Show Full IntroductionHide Full Introduction